This is a $335,333,551.74 definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Takeda Vaccines Inc. for the development of a Zika virus vaccine. The contract has a period of performance through September 30, 2024. It is a cost-plus-fixed-fee contract with no set-aside designation.
The contract supports ASPR's Zika virus research and vaccine development initiatives. As the prime contractor, Takeda Vaccines Inc. is leading the effort and has engaged a number of subcontractors to provide specialized services such as:
- IQVIA Government Solutions Inc. for Zika-specific assay development, qualification, and validation
- University of Pittsburgh for research on Zika virus neutralizing antibodies
- Charles River Laboratories, Alpha Genesis, and other CROs for animal model studies and virology testing
This major contract award reflects the U.S. government's ongoing focus on enhancing pandemic preparedness and developing medical countermeasures against emerging infectious disease threats like Zika virus.
Generated 9/27/24, 9:03 AM